About SIGA Technologies
SIGA Technologies is a publicly listed company based in New York (United States) founded in 1995. Anti-infective therapeutics for bio-warfare threats are developed. The company has 39 employees. SIGA Technologies offers products and services including TPOXX. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its legal entity is SIGA TECHNOLOGIES INC. Its competitors include Moderna, Adaptive Biotechnologies and Novavax; 2 of its 3 listed competitors have raised funding.
Company details
SIGA Technologies was founded in 1995 and is headquartered in New York, United States. Operations focus on the biotechnology sector, where anti-infective therapeutics targeting biological warfare threats are developed. A lead candidate, TPOXX (tecovirimat), is offered to inhibit viral spread, thereby preventing disease symptoms in animal models of smallpox. The companys domain is siga.com.
- Annual Revenue$737.68 K (USD)-99as on Dec 31, 2024
- Net Profit$59.21 M (USD)-13as on Dec 31, 2024
- EBITDA$69.98 M (USD)-16as on Dec 31, 2024
- Latest Funding Round$115M (USD), Debt – Conventional
Nov 2016
- InvestorsNIH
& 3 more
- Employee Count39
Products & Services of SIGA Technologies
SIGA Technologies offers a comprehensive portfolio of products and services, including TPOXX.
Treats orthopoxvirus infections by preventing viral spread.
Funding Insights of SIGA Technologies
- Total Rounds 15
- Last Round Debt – Conventional — $115M
- First Round $125,000
(Oct 2000)
- Investors Count 4
Latest 10 of 15 funding rounds of SIGA Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2016 | $115M | Debt – Conventional | – | – | – |
| Aug 2011 | $7.7M | Grant | – | – | |
| Aug 2011 | $7.11M | Grant | – | – | |
| May 2011 | $5.81M | Grant | – | – | |
| Dec 2009 | $18.6M | Post-IPO | – | – | – |
| Sep 2009 | $1.67M | Grant | – | – | |
| Sep 2009 | $3M | Grant | – | – | |
| Aug 2009 | $3M | Grant | – | – | |
| Jul 2009 | $963,737 | Grant | – | – | |
| Sep 2008 | $20M | Grant | – | – |
4 investors in total: 4 institutional.
Investors in SIGA Technologies
SIGA Technologies has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and SBIR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
| niaid.nih.gov | ||||
Federal innovation and scientific achievement services are provided. | 1982 | sbir.gov | Lithia Springs, United States |
Investor details for SIGA Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of SIGA Technologies
35 people are tracked at SIGA Technologies (17 in leadership, 8 in board & advisors, 10 in team); the tracked headcount is 39.
| Name | Role | Group |
|---|---|---|
Daniel J. Luckshire | Executive Vice President and Chief Financial Officer | Leadership |
Phillip Louis Gomez III | CEO | Leadership |
Katie Abresch | Director Of Business Operations | Leadership |
Dennis E. Hruby | EVP & Chief Scientific Officer | Leadership |
Mary Hunsaker | Director of Finance and Cost Accounting | Leadership |
Candace Lovejoy | Associate Director, Contracts & Project Management | Leadership |
Annie O. | Human Resources Director | Leadership |
Emily Blum | Director, Clinical Development | Leadership |
Lek Chinsangaram | Senior Director, Project Management | Leadership |
Jay Vosler | Director of Accounting | Leadership |
Edmund O. | Chief Information Officer | Leadership |
Doug Grosenbach | Senior Director, Poxvirus Research | Leadership |
Tove Bolken | Senior Vice President, Operations & Chief Supply Chain Officer | Leadership |
Kevin Buckley | VP Controller | Leadership |
Laird Novak | Senior Director of IT Systems & Security | Leadership |
Sarah Hurley | Senior Director Quality Assurance | Leadership |
Thomas Losito Jr. | Director, Supply Chain | Leadership |
Joseph W. Chip Marshall, III | Independent Director | Board & advisors |
Gary J. Nabel | Director | Board & advisors |
Jay K. Varma | Director | Board & advisors |
15 more people are available in the full profile.
Complete people profiles for SIGA Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of SIGA Technologies
SIGA Technologies is a publicly listed company on the NASDAQ with ticker symbol SIGA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date09 Sep 1997
- Listed onNASDAQ: SIGA
- Listed entitySIGA Technologies Inc.
- Exchange sectorHealth technology
Timeline of SIGA Technologies
4 dated milestones of SIGA Technologies across 21 years, from founding to its latest funding, stage changes and deals.
- Founded SIGA Technologies is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $125K.
- Funding Latest funding round, Debt – Conventional, of $115.0M.
Competitors of SIGA Technologies
SIGA Technologies has 3 listed competitors in our database, 2 of them funded. They include Moderna, Adaptive Biotechnologies and Novavax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| adaptivebiotech.com | 2009 | Seattle, United States | $419.15M | 609 | Clinical diagnostics and drug discovery for immune diseases are provided. | |
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. |
Detailed competitors of SIGA Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SIGA Technologies
The website of SIGA Technologies (siga.com) receives about 8.4K visits a month and ranks #3,215,987 among all websites worldwide, #4,226 in Biotechnology and Pharmaceuticals.
- Monthly visits8.4K
▲ 36.1% vs previous month
- Unique visitors2.8K
per month
- Global rank#3,215,987
among all websites
- Category rank#4,226
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.7
- Average visit13 sec
- DevicesDesktop 45% · Mobile 55%
Websites whose visitors overlap most with SIGA Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
gemacbio.com | gemacbio.com | 100% | – | ||
| xoma.com | 100% | 8K | #3,718,828 | View details | |
| zymogenetics.com | 100% | View details | |||
| xencor.com | 100% | 22.2K | #2,563,685 | View details | |
| neurocrine.com | 100% | 39.1K | #927,855 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for SIGA Technologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as SIGA Technologies (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Siga Technologies
Complete news archive for SIGA Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SIGA Technologies
SIGA Technologies was founded in 1995 and raised its 1st funding round 5 years after it was founded.
SIGA Technologies is headquartered in New York, United States. It is registered at New York, New York, United States.
SIGA Technologies has 39 employees.
Annual revenue of SIGA Technologies is $737.68K as on Dec 31, 2024.
SIGA Technologies was founded in 1995 and is headquartered in New York, United States. Operations focus on the biotechnology sector, where anti-infective therapeutics targeting biological warfare threats are developed. A lead candidate, TPOXX (tecovirimat), is offered to inhibit viral spread, thereby preventing disease symptoms in animal models of smallpox. The companys domain is siga.com.
SIGA Technologies's top competitors include Moderna, Adaptive Biotechnologies and Novavax.
SIGA Technologies offers TPOXX.
Yes, SIGA Technologies is publicly traded on NASDAQ under the ticker symbol SIGA.
SIGA Technologies operates through Siga Technologies Inc.